But what, if any, is the role of statin therapy for patients at low cardiovascular risk? Would any benefit be clinically efficacious, safe and cost-effective? The key question is: should GPs be prescribing statins for ‘healthy’ patients at low cardiovascular risk?
This controversial topic was in part answered by the recent published JUPITER (Justification for the Use of Statins in Primary Prevention: an Interventional Trial Evaluating Rosuvastatin) study.
JUPITER was a large placebo-controlled RCT that included 17 802 ‘healthy’ individuals from 26...]]>
During the last 50 years, the treatment of myocardial infarction has evolved. Monitoring of arrhythmias,